Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab in ER+/PR+, HER2- Metastatic Breast Cancer With Bone Metastases
NCT03070002Phase 2Terminated
- Sponsor
- Northwestern University
- Start
- Oct 2017
- Primary completion
- Mar 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of denosumab in breast cancer, sponsored by Northwestern University. Started Oct 2017; status: terminated.
02
Drugs
denosumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03070002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03070002.